Effect of Gum Arabic on Gastrointestinal Transit and Permeability
Study Details
Study Description
Brief Summary
The study aims to determine the effect of gum arabic on gut bacteria and GI function.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
To compare the effect of placebo, low-dose prebiotic, or high-dose prebiotic on gut microbiota composition and function, GI transit and permeability, and assess development of symptoms or a change in pre-existing symptoms present, in patients with recent history of clinically diagnosed diverticulitis which has been successfully treated.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: High-dose prebiotic 10 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks |
Dietary Supplement: High-dose prebiotic
This is a spray-dried powder, yellowish-white in color, that is dissolvable.
Other Names:
|
| Active Comparator: Low-dose prebiotic 5 gm gum arabic (powder) with 2 gm fiber powder daily for at least 6 weeks |
Dietary Supplement: Low-dose prebiotic
This is a spray-dried powder, yellowish-white in color, that is dissolvable.
Other Names:
|
| Placebo Comparator: Placebo 2 gm powdered fiber daily for at least 6 weeks |
Dietary Supplement: Placebo
Powder fiber supplement, yellowish-white in color, that is dissolvable.
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Colonic Transit time [Change is being assessed between baseline and 6 weeks]
The scintigraphic method is used to measure colonic transit. An isotope is adsorbed on activated charcoal particles and delivered to the colon in a delayed release capsule. Anterior and posterior gamma images are taken hourly. The geometric center (GC) is the weighted average of counts in the different colonic regions. The scale ranges from 1 to 5; a high GC implies faster colonic transit, a GC of 1 implies all isotope is in the ascending colon, and a GC of 5 implies all isotope is in the stool. Units: units on a scale
Secondary Outcome Measures
- Intestinal Permeability [Change is being assessed between baseline and 6 weeks]
To determine intestinal permeability, urine will be collected for 24 hours after drinking a sugar solution. The 0- to 2-hour urine most closely reflects small intestinal permeability and the 8- to 24-hour urine reflects colonic permeability. HPLC-tandem mass spectrometry will be used for detection of the sugars.
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Recent diagnosis of diverticulitis (within 24 months) and at least 4 weeks post antibiotic use
-
Age 18-80
Exclusion Criteria:
-
Prior history of gastrointestinal surgeries (except appendectomy and cholecystectomy)
-
Known diagnosis of inflammatory bowel disease (Crohn's or ulcerative colitis), microscopic colitis, celiac disease, or other inflammatory condition other than diverticulitis
-
Use of tobacco products within the past 6 months (since nicotine may affect intestinal permeability)
-
Use of NSAIDs or aspirin within the week prior to Visit 2 and Visit 5 (permeability and transit testing visit since NSAIDs affect intestinal permeability)
-
Use of osmotic laxatives one week prior to Visit 2 and for the duration of the study
-
Use of oral corticosteroids within the previous 6 weeks and for the duration of the study
-
Ingestion of artificial sweeteners such as Splenda™ (sucralose), Nutrasweet™ (aspartame), sorbitol, xylitol, lactulose, or mannitol 2 days before and during the permeability testing days, e.g. foods to be avoided are sugarless gums or mints and diet beverages
-
Antibiotic use within 4 weeks of completion of the initial stool kit and/or Visit 2 testing appointment and for the remainder of the study (they can complete the stool kit and Visit 2 after a 4-week washout period)
-
Bowel preparation for colonoscopy less than one week prior to the completion of the first stool kit and Visit 2 and during the remainder of the study
-
Pregnancy or plan to become pregnant within the study timeframe
-
Vulnerable adults
-
Egg allergy or resistant to ingesting eggs
-
Diagnosis of diabetes
-
Any other disease(s), condition(s) or habit(s) that would interfere with completion of study, or in the judgment of the investigator would potentially interfere with compliance to this study or would adversely affect study outcomes
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | Mayo Clinic in Rochester | Rochester | Minnesota | United States | 55905 |
Sponsors and Collaborators
- Mayo Clinic
Investigators
- Principal Investigator: Purna C Kashyap, MBBS, Mayo Clinic
Study Documents (Full-Text)
None provided.More Information
Additional Information:
Publications
None provided.- 18-001008